ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
3 hedge funds and large institutions have $13.1K invested in ELITE PHARMACEUTICAL in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
183% more capital invested
Capital invested by funds: $4.64K → $13.1K (+$8.5K)
50% more funds holding
Funds holding: 2 → 3 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JAFL
1
Jay A. Fishman Ltd
Troy,
Michigan
| $5.14K | – | – | – |
|
|
HCM
2
Highlander Capital Management
Short Hills,
New Jersey
| $4K | – | – | – |
|
|
3
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $4K | +$4K | +48,778 | New |
|
ELI Hedge Fund Activity: Q3 2019 in Review
3 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2019, worth a combined $13.1K — up 183% from $4.64K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $4K.
- 3 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q3 2019, up from 2 in Q2 2019.
- Funds reported $13.1K of ELITE PHARMACEUTICAL stock for Q3 2019, up 183% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q3 2019 and 0 closed out, a net change of +1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q3 2019 was CAPTRUST Financial Advisors, an estimated $4K added.
Based on aggregated 13F filings for Q3 2019.